胃肠病学和肝病学杂志

参考文献

[1] Siegel R L,Giaquinto A N,Jemal A.Cancer statistics,2024 [J].CA Cancer J Clin,2024,74(1):12-49.

[2] Mizrahi J D,Surana R,Valle J W,et al.Pancreatic cancer [J].Lancet,2020,395(10242):2008-2020.

[3] Gu M,Ren B,Fang Y,et al.Epigenetic regulation in cancer [J].MedComm,2024,5(2):e495.

[4] Bracken A P,Brien G L,Verrijzer C P.Dangerous liaisons:interplay between SWI/SNF,NuRD,and Polycomb in chromatin regulation and cancer [J].Genes Dev,2019,33(15-16):936-959.

[5] Lomberk G,Blum Y,Nicolle R,et al.Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes [J].Nat Commun,2018,9(1):1978.

[6] Eustermann S,Patel A B,Hopfner K P,et al.Energy-driven genome regulation by ATP-dependent chromatin remodellers [J].Nat Rev Mol Cell Biol,2024,25(4):309-332.

[7] Michel B C,D′Avino A R,Cassel S H,et al.A non-canonical SWI/SNF complex is a synthetic lethal target in cancers driven by BAF complex perturbation [J].Nat Cell Biol,2018,20(12):1410-1420.

[8] Mittal P,Roberts C W M.The SWI/SNF complex in cancer—biology,biomarkers and therapy [J].Nat Rev Clin Oncol,2020,17(7):435-448.

[9] Centore R C,Sandoval G J,Soares L M M,et al.Mammalian SWI/SNF chromatin remodeling complexes:emerging mechanisms and therapeutic strategies [J].Trends Genet,2020,36(12):936-950.

[10] Yavas A,Ozcan K,Adsay N V,et al.SWI/SNF complex-deficient undifferentiated carcinoma of the pancreas:clinicopathologic and genomic analysis [J].Mod Pathol,2024,37(11):100585.

[11] Guerrero-Martínez J A,Reyes J C.High expression of SMARCA4 or SMARCA2 is frequently associated with an opposite prognosis in cancer [J].Sci Rep,2018,8(1):2043.

[12] Zhang Z,Li J,Guo H,et al.BRM transcriptionally regulates miR-302a-3p to target SOCS5/STAT3 signaling axis to potentiate pancreatic cancer metastasis [J].Cancer Lett,2019,449:215-225.

[13] Zhang Z,Wang F,Du C,et al.BRM/SMARCA2 promotes the proliferation and chemoresistance of pancreatic cancer cells by targeting JAK2/STAT3 signaling [J].Cancer Lett,2017,402:213-224.

[14] Spaeth J M,Liu J H,Peters D,et al.The Pdx1-bound swi/snf chromatin remodeling complex regulates pancreatic progenitor cell proliferation and mature islet β-cell function [J].Diabetes,2019,68(9):1806-1818.

[15] Numata M,Morinaga S,Watanabe T,et al.The clinical significance of SWI/SNF complex in pancreatic cancer [J].Int J Oncol,2013,42(2):403-410.

[16] Liu X,Tian X,Wang F,et al.BRG1 promotes chemoresistance of pancreatic cancer cells through crosstalking with Akt signalling [J].Eur J Cancer,2014,50(13):2251-2262.

[17] Roy N,Malik S,Villanueva K E,et al.Brg1 promotes both tumor-suppressive and oncogenic activities at distinct stages of pancreatic cancer formation [J].Genes Dev,2015,29(6):658-671.

[18] Araki O,Tsuda M,Omatsu M,et al.Brg1 controls stemness and metastasis of pancreatic cancer through regulating hypoxia pathway [J].Oncogene,2023,42(26):2139-2152.

[19] Kimura Y,Fukuda A,Ogawa S,et al.ARID1A maintains differentiation of pancreatic ductal cells and inhibits development of pancreatic ductal adenocarcinoma in mice [J].Gastroenterology,2018,155(1):194-209.e2.

[20] Wang S C,Nassour I,Xiao S,et al.SWI/SNF component ARID1A restrains pancreatic neoplasia formation [J].Gut,2019,68(7):1259-1270.

[21] Bailey P,Chang D K,Nones K,et al.Genomic analyses identify molecular subtypes of pancreatic cancer [J].Nature,2016,531(7592):47-52.

[22] Raphael B J,Hruban R H,Aguirre A J,et al.Integrated genomic characterization of pancreatic ductal adenocarcinoma [J].Cancer Cell,2017,32(2):185-203.e13.

[23] Kawai M,Fukuda A,Ikeda M,et al.Polybromo 1/vimentin axis dictates tumor grade,epithelial-mesenchymal transition,and metastasis in pancreatic cancer [J].J Clin Invest,2025,135(11):e177533.

[24] Clapier C R,Iwasa J,Cairns B R,et al.Mechanisms of action and regulation of ATP-dependent chromatin-remodelling complexes [J].Nat Rev Mol Cell Biol,2017,18(7):407-422.

[25] Li Y,Gong H,Wang P,et al.The emerging role of ISWI chromatin remodeling complexes in cancer [J].J Exp Clin Cancer Res,2021,40(1):346.

[26] Oppikofer M,Bai T,Gan Y,et al.Expansion of the ISWI chromatin remodeler family with new active complexes [J].EMBO Rep,2017,18(10):1697-1706.

[27] Dar A A,Nosrati M,Bezrookove V,et al.The role of BPTF in melanoma progression and in response to BRAF-targeted therapy [J].J Natl Cancer Inst,2015,107(5):djv034.

[28] Xiao S,Liu L,Lu X,et al.The prognostic significance of bromodomain PHD-finger transcription factor in colorectal carcinoma and association with vimentin and E-cadherin [J].J Cancer Res Clin Oncol,2015,141(8):1465-1474.

[29] Richart L,Pau E C S,Río-Machín A,et al.BPTF is required for c-MYC transcriptional activity and in vivo tumorigenesis [J].Nat Commun,2016,7:10153.

[30] Xia L,Huang W,Bellani M,et al.CHD4 has oncogenic functions in initiating and maintaining epigenetic suppression of multiple tumor suppressor genes [J].Cancer Cell,2017,31(5):653-668.e7.

[31] Chaudhary K,Deb S,Moniaux N,et al.Human RNA polymerase Ⅱ-associated factor complex:dysregulation in cancer [J].Oncogene,2007,26(54):7499-7507.

[32] Dey P,Ponnusamy M P,Deb S,et al.Human RNA polymerase Ⅱ-association factor 1 (hPaf1/PD2) regulates histone methylation and chromatin remodeling in pancreatic cancer [J].PLoS One,2011,6(10):e26926.

[33] Hall W A,Petrova A V,Colbert L E,et al.Low CHD5 expression activates the DNA damage response and predicts poor outcome in patients undergoing adjuvant therapy for resected pancreatic cancer [J].Oncogene,2014,33(47):5450-5456.

[34] Du Z,Li L,Huang X,et al.The epigenetic modifier CHD5 functions as a novel tumor suppressor for renal cell carcinoma and is predominantly inactivated by promoter CpG methylation [J].Oncotarget,2016,7(16):21618-21630.

[35] Zhang C,Peng K,Liu Q,et al.Adavosertib and beyond:biomarkers,drug combination and toxicity of WEE1 inhibitors [J].Crit Rev Oncol Hematol,2024,193:104233.

[36] Quan J,Adelmant G,Marto J A,et al.The chromatin remodeling factor CHD5 is a transcriptional repressor of WEE1 [J].PLoS One,2014,9(9):e108066.

[37] Cuneo K C,Morgan M A,Sahai V,et al.Dose escalation trial of the Wee1 inhibitor adavosertib (AZD1775) in combination with gemcitabine and radiation for patients with locally advanced pancreatic cancer [J].J Clin Oncol,2019,37(29):2643-2650.

[38] Mishra N K,Guda C.Genome-wide DNA methylation analysis reveals molecular subtypes of pancreatic cancer [J].Oncotarget,2017,8(17):28990-29012.

[39] Wu D,Tan H,Su W,et al.MZF1 mediates oncogene-induced senescence by promoting the transcription of p16INK4A [J].Oncogene,2022,41(3):414-426.

[40] Willhoft O,Wigley D B.INO80 and SWR1 complexes:the non-identical twins of chromatin remodelling [J].Curr Opin Struct Biol,2020,61:50-58.

[41] Zhou B,Wang L,Zhang S,et al.INO80 governs superenhancer-mediated oncogenic transcription and tumor growth in melanoma [J].Genes Dev,2016,30(12):1440-1453.

[42] Zhang S,Zhou B,Wang L,et al.INO80 is required for oncogenic transcription and tumor growth in non-small cell lung cancer [J].Oncogene,2017,36(10):1430-1439.

[43] Lee S A,Lee H S,Hur S K,et al.INO80 haploinsufficiency inhibits colon cancer tumorigenesis via replication stress-induced apoptosis [J].Oncotarget,2017,8(70):115041-115053.

[44] Yau E H,Kummetha I R,Lichinchi G,et al.Genome-wide CRISPR screen for essential cell growth mediators in mutant KRAS colorectal cancers [J].Cancer Res,2017,77(22):6330-6339.